BioXcel Therapeutics, Inc.
BTAIOther · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $642,000 | $2.3M | $1.4M | $375,000 | — | — |
| Operating income | −$50.5M | −$67.2M | −$171.8M | −$159.6M | −$106.9M | −$82.3M |
| Net income | −$69.9M | −$59.6M | −$179.1M | −$165.8M | −$106.9M | −$82.2M |
| Total assets | $44.9M | $38.3M | $73.7M | $205.9M | $239.4M | $219.9M |
| Total liabilities | $140.4M | $131.4M | $130.2M | $129.1M | $17.8M | $13.2M |
| Equity | −$95.5M | −$93.1M | −$56.5M | $76.8M | $221.7M | $206.7M |
| EPS (diluted) | $-5.73 | $-23.51 | $-98.33 | $-5.92 | $-4.05 | $-3.79 |
| Shares out. | 5.5M | 30.6M | 29.0M | 28.0M | 24.6M | 20.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −7860.0%
- Net margin
- −10887.4%
- Return on equity
- 73.2%
- Return on assets
- −155.6%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 312.5%
- Debt / equity
- —
- Book value / share
- $-17.40
- Revenue growth (YoY)
- −71.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -61.88distress
- Accruals / assets
- −27.3%clean
- Beneish M-Score
- -0.60elevated
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 6 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Yocca FrankOfficer — Chief Scientific Officer | May 4, 2026 | Option exercise | 17,500 | — |
| Rodriguez JavierOfficer — See Remarks | May 4, 2026 | Option exercise | 17,500 | — |
| Steinhart Richard IOfficer — Chief Financial Officer | May 4, 2026 | Option exercise | 17,500 | — |
| Mehta VimalOfficer — CEO and President | May 4, 2026 | Option exercise | 49,758 | — |
| Mehta VimalOfficer — CEO and President | May 1, 2026 | Option exercise | 18,000 | — |
| Steinhart Richard IOfficer — Chief Financial Officer | May 1, 2026 | Option exercise | 9,000 | — |
| Yocca FrankOfficer — Chief Scientific Officer | May 1, 2026 | Option exercise | 9,000 | — |
| Rodriguez JavierOfficer — See Remarks | May 1, 2026 | Option exercise | 9,000 | — |
| Mehta VimalOfficer — CEO and President | Mar 14, 2026 | Option exercise | 164 | — |
| Steinhart Richard IOfficer — Chief Financial Officer | Mar 14, 2026 | Option exercise | 33 | — |
| Rodriguez JavierOfficer — See Remarks | Mar 14, 2026 | Option exercise | 33 | — |
| Yocca FrankOfficer — Chief Scientific Officer | Mar 14, 2026 | Option exercise | 33 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.6M | 5.7 | -16.2% |
| Apr 30, 2026 | 4.2M | 4.8 | +7.5% |
| Apr 15, 2026 | 3.9M | 3.1 | +19.2% |
| Mar 31, 2026 | 3.3M | 4.6 | +18.1% |
| Mar 13, 2026 | 2.8M | 1.0 | +49.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 15, 2026
- Unregistered equity saleApr 17, 2026
- Other material eventApr 1, 2026
- Results of operationsMar 27, 2026
- Entered a material agreementMar 11, 2026
- Other material eventFeb 12, 2026
- Director / officer changeFeb 6, 2026
- Other material eventJan 20, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4OWNERSHIP DOCUMENTMay 22, 2026
- 4OWNERSHIP DOCUMENTMay 22, 2026
- 4OWNERSHIP DOCUMENTMay 22, 2026
- 4OWNERSHIP DOCUMENTMay 22, 2026
- 144May 20, 2026
- 144May 20, 2026
- 144May 20, 2026
- 144May 20, 2026
- SCHEDULE 13GMay 15, 2026
- 8-KFORM 8-KMay 15, 2026
- 10-QMay 15, 2026
- 4OWNERSHIP DOCUMENTMay 7, 2026
- 4OWNERSHIP DOCUMENTMay 7, 2026
- 4OWNERSHIP DOCUMENTMay 7, 2026
- 4OWNERSHIP DOCUMENTMay 7, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.